Gregg L. Semenza, M.D., Ph.D.

Director, Vascular Program, Institute for Cell Engineering; Professor of Genetic MedicineJohns Hopkins University School of Medicine

Dr. Semenza received an A.B. in Biology magna cum laude from Harvard College; M.D. and Ph.D. (in Genetics) degrees from the University of Pennsylvania; pediatrics residency training at Duke University; and postdoctoral training in medical genetics at the Johns Hopkins University School of Medicine, where he has spent his entire faculty career. He is currently an American Cancer Society Research Professor and the C. Michael Armstrong Professor at Johns Hopkins with appointments in Genetic Medicine, Pediatrics, Medicine, Oncology, Radiation Oncology, and Biological Chemistry; since 2003, he has served as founding Director of the Vascular Program in the Johns Hopkins Institute for Cell Engineering.

Dr. Semenza has been elected to the Society for Pediatric Research, American Society for Clinical Investigation, Association of American Physicians, National Academy of Medicine, and National Academy of Sciences. He has received the Canada-Gairdner International Award, Lefoulon-Delalande Grand Prix Scientifique from the Institut de France, Wiley Prize for Biomedical Sciences, and Albert Lasker Basic Medical Research Award. He has published more than 400 papers, which have been cited over 100,000 times.

Dr. Semenza’s laboratory discovered hypoxia-inducible factor 1 (HIF-1), a master regulator that directs transcriptional responses to decreased oxygen availability in all metazoan species. His lab has shown that HIF-1 plays important roles in cardiovascular disorders, cancer, COPD, diabetes, sleep apnea, transplant rejection, ocular neovascularization and hematologic disorders. His lab is currently investigating the role of HIF-1 in breast cancer progression. In 2017 Dr. Semenza founded HIF Therapeutics Inc. to develop HIF-1 inhibitor nanoparticles for the treatment of cancer and eye diseases.
Sessions
Jan 01 12:00 AM